Incomplete picture hampering long COVID response Data gaps and inconsistent clinical definitions are hampering efforts to manage the increasingly prevalent condition.
Molnupiravir to be used only as a last resort: Taskforce Advice has changed for the country’s most prescribed COVID-19 oral antiviral, although access via the PBS will remain in place.
Health officials laud ‘invaluable’ contribution to pandemic response Three of Australia’s top health officials have thanked GPs for their pivotal role in combatting COVID over the past three years.
Will COVID nasal sprays soon help prevent and treat infection? Virology and infectious diseases expert Dr Lara Herrero looks at the latest science surrounding a potential new treatment.
What can we expect from the latest COVID wave? How long is the new wave likely to last? As case numbers continue to rise, UNSW academic James Wood looks at the most probable outcomes.
MBS clarity needed to boost long COVID care: RACGP Medicare flaws must be addressed to help mitigate the ‘far reaching’ impact of long COVID, a college submission to Parliament has said.
Long COVID risk similar for kids and adults: Study With Australia in the midst of a new wave of infections, research has revealed the extent of post-COVID morbidity in children and adolescents.
Second bivalent booster receives ATAGI recommendation The vaccine will become available in December and is recommended for people who have not had their first or second booster doses.
Vast majority of Australian population has had COVID: Seroprevalence survey Upwards of eight in 10 people have at some point likely contracted the disease, which is now the third leading cause of death nationwide.
‘A positive step’: oral antivirals confirmed for Doctor’s Bag After extensive RACGP lobbying, GPs now have enhanced access to COVID-19 oral antiviral treatments for urgent use among at-risk patients.